Heart failure (HF) represents a complex clinical syndrome affecting multiple organs and
systems of the body, which is a global public health concern because of its high prevalence …

Background Sodium–glucose co-transporter-2 (SGLT2) inhibitors have been studied in
patients with heart failure, type 2 diabetes, chronic kidney disease, atherosclerotic …

Background Because clinical characteristics and prognosis vary by geographic region in
patients with heart failure (HF), the response to treatment may also vary. A previous report …

The prevalence of heart failure is increasing, causing a tremendous burden on health care
systems around the world. Although mortality rate of heart failure has been significantly …

Background Patients with heart failure (HF) with mildly reduced or preserved ejection
fraction in Asia may have different clinical characteristics and outcomes compared with …

The prevalence of type 2 diabetes mellitus continues to increase in many Asian countries,
with possible contributing factors, such as younger‐onset disease, diabetes development at …

The global burden of heart failure (HF), which has an estimated prevalence of 1% to 3% 1
and an increasing incidence assessed at 1 to 20 cases per 1,000 person-years, 1 severely …

Heart failure (HF) is a global epidemic. In 2017, estimates suggested HF affected over 64
million people worldwide, a dramatic increase from 33.5 million in 1990. 1 HF as a disease …

Heart failure (HF) is a clinical syndrome that consists of cardinal symptoms and the
accompanying signs. HF poses a significant health and economic burden as it affects …